OakChart

IN8bio Inc

INABHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 9:54 AM ET

0.8855-0.0145 (-1.61%)
2026-11-11 16:00 CET
Market cap
9.73 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-19.41 USD m
Free cash flow, TTM
-15.00 USD m
EPS diluted, TTM
-1.25
P/E
-
Compare

Price

INAB against its 20, 50 and 200-day averages
2050200miss
1.001.50188K376KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INABclose 0.8920-day 0.9950-day 1.12200-day 1.400.89

67.5% under 2.73 on 16 Jan 2026. Last 15 sessions, 36.3% high to low

Profile

INAB
52-week range, 4% of the way up
0.802.73

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates for solid and liquid tumors and gamma-delta T cell engagers for cancer and autoimmune diseases. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Employees17
IPOJul 30, 2021
Beta0.24
ATR, 14d0.09
Rel volume0.04
Short float0.16%
Insider own7.35%
Inst own34.73%

Snapshot

6 groups

Valuation

Index-
Market Cap9.57M
Enterprise Value-1.65M
Income-19.41M
Sales0.00M
Book/sh1.44
Cash/sh1.29
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees17
IPOJul 30, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.62
P/C0.69
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.78
Current Ratio5.78
Debt/Eq0.19
LT Debt/Eq0.13
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.25
EPS next Y-0.94
EPS next Q-0.36
EPS this Y74.47%
EPS next Y17.06%
EPS next 5Y55.55%
EPS past 3/5Y52.25% 22.63%
Sales past 3/5Y- -
EPS Y/Y TTM81.16%
Sales Y/Y TTM-
EPS Q/Q72.24%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.28.72% -

Ownership

Insider Own7.35%
Insider Trans0.00%
Inst Own34.73%
Inst Trans-5.90%
ROA-109.44%
ROE-141.83%
ROIC-120.78%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-10.33%
SMA50-20.68%
SMA200-36.60%
Trades-

Technical

Shs Outstand10.81M
Shs Float10.01M
Short Float0.16%
Short Ratio0.31
Short Interest0.02M
52W High2.73 -67.56%
52W Low0.80 10.69%
Volatility9.38% 8.75%
ATR (14)0.09
RSI (14)38.71
Beta0.24
Rel Volume0.04
Avg Volume50.35K
Volume241

Performance

Perf Week-4.86%
Perf Month-24.96%
Perf Quarter-24.96%
Perf Half Y-44.31%
Perf YTD-62.16%
Perf Year-47.29%
Perf 3Y-97.16%
Perf 5Y-99.64%
Perf 10Y-
Recom1.00
Target Price7.00
Prev Close0.90
Price0.89
Change %-1.61%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Mar 18, 2024InitiatedLLaidlawBuy$7.50+747.0%
Aug 30, 2022InitiatedHH.C. WainwrightBuy$14+1,481.0%

Peers

Mkt cap
TickerCompanyMkt cap
ACETAdicet Bio Inc27.85M
GDTCCytoMed Therapeutics Ltd9.89M
MRKRMarker Therapeutics Inc16.00M
TCRXTscan Therapeutics Inc12.63M
INKTMiNK Therapeutics Inc52.10M
ESLAEstrella Immunopharma Inc36.97M
CRBUCaribou Biosciences Inc41.10M
NKTXNkarta Inc97.52M
ATRAAtara Biotherapeutics Inc80.56M
IPSCCentury Therapeutics Inc305.30M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B

News

latest 14 of 206
  • IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.63%
  • IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -10.82%
  • IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • IN8bio to Present at Sidoti Small-Cap Virtual Conference (GlobeNewswire) +7.55%
  • IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Loading…
  • IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development (GlobeNewswire) -5.26%
  • IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.59%
  • IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
  • IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma (GlobeNewswire)
  • IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies (GlobeNewswire)
  • IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 (GlobeNewswire) -7.49%
  • IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma (GlobeNewswire)
  • IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.240-0.337-0.2400.000.003
2026Q22026-08-06-0.250-0.344-0.2460.000.004
2026Q12026-05-07-0.260-0.618-0.2620.000.003
2025Q42026-03-12-0.450-0.641-0.5060.000.004
2025Q32025-11-06-0.850-1.084-0.8490.000.003
2025Q22025-08-07-1.240-1.725-1.2370.000.004
2025Q12025-05-07-2.100-2.025-1.9940.000.004
2024Q42025-03-13-2.400-2.151-2.5500.000.006
2024Q32024-11-12-4.500-5.100-4.4920.000.003
2024Q22024-08-08-5.700-5.199-5.7370.000.006
2024Q12024-05-09-6.000-5.040-5.9340.000.005
2023Q42024-03-14-6.600-4.599-6.3670.000.003
2023Q32023-11-09-6.900-7.350-6.8180.000.002
2023Q22023-08-10-8.100-8.100-8.1290.000.003
2023Q12023-05-12-9.000-9.600-9.1280.000.003
2022Q42023-03-30-9.600-9.501-9.5310.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-44.100-46.800-23.4060.000.00
2022FY-40.800-40.899-40.8070.000.00
2023FY-30.000-27.099-30.1430.000.00
2024FY-17.100-16.900-17.0530.000.00
2025FY-4.440-2.608-0.7700.000.00
2026FY--1.133--0.00
2027FY--0.940--1.66
2028FY--0.390--16.32
2029FY-0.320--59.95
2030FY-0.640--83.46

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-062000.000.000.00
2026Q4S2026-11-052000.000.000.00
2026Q4S2026-09-142000.000.000.00
2026Q4S2026-08-073000.000.000.00
2026Q4S2026-05-083000.000.000.00
2026Q4S2026-05-011000.000.000.00
2026Q4S2026-03-132000.000.000.00
2026Q4S2026-01-212000.000.000.00
2026Q4S2026-01-121000.000.000.00
2026Q4R2026-11-06101-0.20-0.20-0.20
2026Q4R2026-11-05100-0.17-0.17-0.17
2026Q4R2026-08-07100-0.17-0.17-0.17
2026Q4R2026-07-22100-0.17-0.17-0.17
2026Q4R2026-05-08101-0.17-0.17-0.17

Estimate history

EPS, annual-3.889-9.164-16.027-23.406-40.807-30.143-17.053-4.444-1.2489
Period20182019202020212022202320242025TTM
EPS, quarterly-4.492-2.55-1.994-1.237-0.849-0.506-0.262-0.246-0.236
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.6450.6450.6450.6260.8181.4432.4169.7669.858
Period20182019202020212022202320242025MRQ
Shares, quarterly1.562.4162.7094.0784.5899.7669.8479.8539.858
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.612.502.652.501.100.250.100.100.10
Gross Profit-2.61-2.50-2.65-2.50-1.10-0.25-0.10-0.10-0.10
Selling, General and Administrative Excl. Other17.3417.3626.9427.8427.4214.408.464.971.91
Research and Development10.3510.2116.9616.8314.067.355.382.360.58
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-19.95-19.86-29.60-30.34-28.52-14.65-8.56-5.07-2.00
Interest Expense-------0.000.01
Unusual Expense0.000.001.070.000.000.000.000.000.00
Net Income Before Taxes-19.41-19.44-30.44-30.01-28.52-14.65-8.56-5.13-2.08
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-19.41-19.44-30.44-30.01-28.52-14.65-8.56-5.13-2.08
Net Income From Continuing Operations-19.41-19.44-30.44-30.01-28.52-14.65-8.56-5.13-2.08
Net Income-19.41-19.44-30.44-30.01-28.52-14.65-10.34-5.91-2.51
EPS (Recurring)-1.00-4.44-16.63-30.14-40.81-23.41-16.03-9.16-3.89
EPS (Basic, Before Extraordinaries)-1.25-4.44-17.05-30.14-40.81-23.41-16.03-9.16-3.89
EPS (Diluted)-1.25-4.44-17.05-30.14-40.81-23.41-16.03-9.16-3.89
EBITDA-17.34-17.36-26.94-27.84-27.42-14.40-8.46-4.97-1.91
Non-Operating Income (Expense)0.550.420.230.330.000.000.00-0.07-0.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.863.195.004.373.472.190.360.080.03
Shares Outstanding9.869.772.421.440.820.630.650.650.65
Market Capitalization9.739.7318.6444.1356.6082.4584.96--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.430.500.501.170.400.500.430.70
Gross Profit-0.43-0.50-0.50-1.17-0.40-0.50-0.43-0.70
Selling, General and Administrative Excl. Other4.294.434.773.863.574.705.235.52
Research and Development2.602.492.612.652.102.492.973.59
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.72-4.93-5.27-5.03-3.97-5.20-5.66-6.22
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-4.59-4.78-5.09-4.94-3.85-5.09-5.55-6.16
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.59-4.78-5.09-4.94-3.85-5.09-5.55-6.16
Net Income From Continuing Operations-4.59-4.78-5.09-4.94-3.85-5.09-5.55-6.16
Net Income-4.59-4.78-5.09-4.94-3.85-5.09-5.55-6.16
EPS (Recurring)-0.24-0.25-0.26-0.51-0.85-1.24-1.99-2.55
EPS (Basic, Before Extraordinaries)-0.24-0.25-0.26-0.51-0.85-1.24-1.99-2.55
EPS (Diluted)-0.24-0.25-0.26-0.51-0.85-1.24-1.99-2.55
EBITDA-4.29-4.43-4.77-3.86-3.57-4.70-5.23-5.52
Non-Operating Income (Expense)0.130.150.180.090.110.110.110.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.400.350.400.710.690.950.830.82
Shares Outstanding9.869.859.859.774.594.082.712.42
Market Capitalization9.7313.8814.5710.849.857.2013.4918.64

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments27.0911.1221.2818.1837.0217.990.614.99
Short Term Receivables0.000.000.000.000.000.000.000.03
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets0.791.463.344.051.960.150.150.05
Total Current Assets27.8812.5824.6222.2338.9818.140.765.07
Net Property, Plant & Equipment4.047.838.5710.302.830.190.270.80
Total Investments and Advances0.220.270.260.250.250.000.000.00
Deferred Tax Assets-1.04------
Other Assets0.150.280.260.260.162.580.090.03
Total Assets32.2821.9933.7133.0442.2220.911.135.89
Short Term Debt Incl. Current Port. of LT Debt1.221.651.511.390.630.170.000.00
Accounts Payable0.310.390.922.090.000.000.000.00
Other Current Liabilities1.631.052.962.341.632.400.650.42
Total Current Liabilities3.163.085.395.822.262.570.650.42
Long Term Debt1.563.383.384.491.780.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities-1.04------
Other Liabilities0.000.000.000.000.000.020.830.83
Total Liabilities4.727.518.7710.314.042.591.481.25
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0034.908.908.90
Common Equity27.5614.4824.9422.7338.18-16.58-9.24-4.25
Total Shareholders Equity27.5614.4824.9422.7338.1818.32-0.354.65
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity27.5614.4824.9422.7338.1818.32-0.354.65
Total Liabilities & Stockholders Equity32.2821.9933.7133.0442.2220.911.135.89
Book Value Per Share2.825.9917.2827.7860.99-25.70-14.33-6.59
Tangible Book Value Per Share2.825.9917.2827.7860.99-25.70-14.33-6.59
Full-Time Employees171831261914--
Price to Book Ratio0.631.292.481.912.161.97--
Return on Assets-71.64-109.30-89.91-75.79-46.42-77.65-146.16-
Return on Equity-92.49-154.44-125.90-93.64-51.87-95.21-238.74-
Return on Invested Capital-66.76-170.41-105.97-104.79-36.66-46.71--44.78
Quick Ratio8.824.084.573.8217.287.051.1812.11
Current Ratio8.824.084.573.8217.287.051.1812.11

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-19.41-19.44-30.44-30.01-28.52-14.65-8.56-5.13-2.08
Depreciation1.912.502.652.501.100.250.090.100.10
Other Funds (Non Cash)1.863.195.044.373.470.040.720.140.10
Funds from Operations-15.63-13.75-22.74-23.14-23.95-14.36-7.74-4.89-1.88
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.871.04-1.41-0.20-0.17-1.840.610.09-0.89
Cash from Operating Activities-14.76-12.71-24.15-23.34-24.12-16.20-7.13-4.80-2.77
Capital Expenditures-0.240.00-0.19-0.60-3.71-0.310.00-0.33-0.76
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.690.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.240.00-0.19-0.60-3.71-0.310.000.36-0.76
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock18.5329.3314.9827.849.6036.3625.690.077.24
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock18.5329.3314.9827.849.6036.3625.690.077.24
Proceedsfrom Stock Options18.5327.079.8514.389.5436.3325.670.007.24
Issuance or Reduction of Debt, Net-0.34-0.69-0.79-0.80-0.61-0.710.170.001.26
Change in Long Term Debt-0.34-0.69-0.79-0.80-0.61-0.710.170.001.26
Issuance of Long Term Debt0.000.000.000.000.000.000.170.002.07
Reduction of Long Term Debt-0.34-0.69-0.79-0.80-0.61-0.710.000.00-0.80
Net Financing Active Other Cash Flow0.000.000.000.000.000.00-1.340.000.00
Other Financing Activities Uses0.000.000.000.000.000.00-1.340.000.00
Cash from Financing Activities18.1928.6414.1827.048.9935.6524.520.078.50
Net Change in Cash3.1915.93-10.153.10-18.8419.1417.38-4.384.97
Free Cash Flow-15.00-12.71-24.34-23.94-27.83-16.51-7.13-5.13-3.53
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments13.9717.9621.9427.0910.6913.23
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.220.540.720.791.080.52
Total Current Assets15.1918.5022.6627.8811.7713.74
Net Property, Plant & Equipment3.222.973.254.044.565.08
Total Investments and Advances0.180.180.220.220.270.27
Other Assets0.100.100.130.150.170.28
Total Assets18.7021.7526.2732.2816.7719.37
Short Term Debt Incl. Current Port. of LT Debt0.861.051.031.221.080.94
Accounts Payable0.490.440.450.310.200.38
Other Current Liabilities1.280.760.681.630.420.64
Total Current Liabilities2.632.252.163.161.701.95
Long Term Debt1.891.131.331.561.882.18
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities4.523.383.484.723.584.13
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity14.1718.3622.7827.5613.1915.24
Total Shareholders Equity14.1718.3622.7827.5613.1915.24
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity14.1718.3622.7827.5613.1915.24
Total Liabilities & Stockholders Equity18.7021.7526.2732.2816.7719.37
Book Value Per Share1.441.862.312.822.873.74
Tangible Book Value Per Share1.441.862.312.822.873.74
Full-Time Employees201818171718
Price to Book Ratio0.630.610.520.810.580.41
Return on Assets-109.44-90.80-82.28-71.64-126.22-114.12
Return on Equity-141.83-111.11-103.55-92.49-189.72-165.56
Return on Invested Capital-28.58-24.53-21.11-16.97-25.58-29.25
Quick Ratio5.788.2110.508.826.917.03
Current Ratio5.788.2110.508.826.917.03

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-4.59-4.78-5.09-4.94-3.85-5.09
Depreciation0.430.460.500.520.530.78
Other Funds (Non Cash)0.400.350.400.710.690.95
Funds from Operations-3.76-3.97-4.19-3.71-2.63-3.35
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.170.23-0.761.57-0.89-0.57
Cash from Operating Activities-3.93-3.75-4.95-2.14-3.52-3.93
Capital Expenditures0.00-0.23-0.010.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.23-0.010.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.010.01-0.0918.601.115.50
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.010.01-0.0918.601.115.50
Proceedsfrom Stock Options0.010.01-0.0918.601.113.62
Issuance or Reduction of Debt, Net-0.06-0.06-0.11-0.11-0.12-0.23
Change in Long Term Debt-0.06-0.06-0.11-0.11-0.12-0.23
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.06-0.06-0.11-0.11-0.12-0.23
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.06-0.05-0.2018.490.995.27
Net Change in Cash-3.98-4.03-5.1516.35-2.541.34
Free Cash Flow-3.93-3.98-4.96-2.14-3.52-3.93

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.16%0.0M10.0M53.10K
2026-10-150.36%0.0M9.1M56.26K
2026-09-300.51%0.0M9.1M57.52K
2026-09-150.69%0.1M9.1M55.04K
2026-08-310.99%0.1M9.1M59.33K
2026-08-141.53%0.1M9.1M64.52K
2026-07-310.29%0.0M8.5M55.88K
2026-07-150.25%0.0M8.5M58.86K
2026-06-300.42%0.0M8.5M58.60K
2026-06-150.54%0.0M8.5M70.76K
2026-05-291.27%0.1M8.5M68.57K
2026-05-152.09%0.2M7.7M61.55K
2026-04-303.21%0.2M7.7M60.59K
2026-04-154.58%0.4M7.7M62.15K
2026-03-313.46%0.3M8.6M77.26K
2026-03-131.86%0.2M8.6M277.01K
2026-02-271.63%0.1M8.5M273.32K
2026-02-131.73%0.1M8.5M277.91K
2026-01-301.97%0.1M6.8M284.88K
2026-01-153.67%0.1M3.2M277.34K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-06-018-KCurrent report2026-05-29SEC
2026-06-01424B5SEC
2026-05-29SCHEDULE 13D/ASEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-19EFFECTEffectiveness filing by commission orderSEC
2026-05-18S-3/ASEC
2026-05-15CORRESPSEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-09SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-09SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-09SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-09SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-09SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-09SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-09SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-09SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-09SEC
2026-05-07S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-05-07S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-05-07S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-05-07S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-05-07S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-05-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Alyeska Investment Group, L.P.9.59%
FRANKLIN RESOURCES INC9.29%
683 Capital Management, LLC7.36%
Stonepine Capital Management, LLC7.06%
VANGUARD CAPITAL MANAGEMENT LLC0.90%
BIOS Capital Management, LP0.82%
CITADEL ADVISORS LLC0.64%
OPPENHEIMER & CO INC0.64%
GEODE CAPITAL MANAGEMENT, LLC0.64%
VANGUARD FIDUCIARY TRUST CO0.44%

Funds

Fund% owned
Franklin Biotechnology Discovery Fund3.37%
VANGUARD EXTENDED MARKET INDEX FUND0.90%
Fidelity Extended Market Index Fund0.47%
Fidelity Series Total Market Index Fund0.12%
Fidelity Total Market Index Fund0.02%
Fidelity Nasdaq Composite Index Fund0.01%
Blackstone Alternative Multi-Strategy Fund0.00%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.00%

OakChart. INAB. Cached 15 minutes.

Some panels did not load: insider.